A medical oncologist at a Southwestern AMC speaks about MRD and monitoring usage and trends for melanoma, breast cancer, colorectal cancer, bladder cancer, and lung cancer. Additionally, they speak to implementation of MRD for hepatocellular cancers. This stakeholder is most familiar with Guardant and Natera tests for MRD. They have an optimistic expectation for the adoption of MRD, specifically for CRC applications, and for monitoring in NSCLC and CRC populations, with the caveat that guidelines will be crucial to widespread adoption across the testing paradigm for all cancer types. Speaking to the landscape of competitors, this stakeholder values customer support and EMR integration, and envisions that the future of MRD and monitoring test selection will be dictated by patient’s preferences in addition to the physician’s vendor knowledge.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care